Allay Tx is developing a drug-eluting biopolymer for sustained post-operative orthopedic pain management.
allaytx.com
Menlo Park, CA
CEO: Adam Gridley
Arboretum lead: Paul McCreadie
Allay Therapeutics
IN THE NEWS
Allay Therapeutics Doses First Patients in Phase 2b Trial of ATX101 for Post-Knee Replacement Pain Management
Allay Therapeutics, a clinical-stage biotechnology company pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation, today announced that the first patient has been dosed in its Phase 2b registration…
Read More
Allay Therapeutics’ Phase 2B Clinical Study Supports Ability of ATX101 To Deliver Four Weeks of Sustained Post-surgical Pain Relief
Allay Therapeutics, a clinical-stage biotechnology company pioneering ultra-sustained analgesic products to transform post-surgical pain management and recuperation, today announced the results from a Phase 2B clinical study of its lead…
Read More
